Placeholder Banner

Provectus starts Phase 1 trial for liver cancer treatment

October 1, 2009
Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) has initiated a Phase 1 study of PV-10 for liver cancer that will enroll up to six subjects with cancer metastatic to the liver or with recurrent liver cancer. PV-10 is the company's lead oncology drug candidate that is also currently undergoing Phase 2 study for metastatic melanoma. The primary objective of the study is to determine the safety and tolerability of a single intralesional injection of PV-10 in patients with cancer of the liver.

Read the release.